Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Eur Heart J ; 37(35): 2713-21, 2016 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-27354043

RESUMO

AIMS: It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine suppresses coronary hyperconstricting responses induced by the first-generation DES (e.g. sirolimus- and pacritaxel-eluting stents) through inhibition of vascular inflammation in pigs. To examine whether this is also the case with the second-generation DES (everolimus-eluting stents, EES) in humans, the most widely used DES in the world, we conducted a prospective, randomized, multicentre trial, termed as the NOVEL Study. METHODS AND RESULTS: We evaluated 100 patients with stable angina pectoris who underwent scheduled implantation of EES in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone or additionally long-acting nifedipine (10-60 mg/day) (n = 50 each). After 8-10 months, 37 patients in the control and 38 in the nifedipine group were examined for coronary vasoreactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-h withdrawal of nifedipine. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal edge of EES compared with non-stented vessel (P = 0.0001) and were significantly suppressed in the nifedipine group compared with the control group (P = 0.0044). Furthermore, the inflammatory profiles were also improved only in the nifedipine group, which evaluated by serum levels of high-sensitivity CRP (P = 0.0001) and adiponectin (P = 0.0039). CONCLUSIONS: These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects. TRIAL REGISTRATION: This study is registered at the UMIN Clinical Trial Registry (UMIN-CTR; ID=UMIN000015147).


Assuntos
Stents Farmacológicos , Doença das Coronárias , Everolimo , Humanos , Nifedipino , Estudos Prospectivos , Sirolimo , Resultado do Tratamento
2.
J Am Chem Soc ; 135(8): 2987-90, 2013 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-23406539

RESUMO

Olefin metathesis is one of the most important industrial processes for the production of alkenes. In contrast, silicon versions of metathesis are unknown given the lack of available silylene transition-metal complexes suitable for [2 + 2] cycloaddition with unsaturated substrates. Here, we report the synthesis of 18-electron titanium silylene complexes featuring different Lewis base ligands and classified on the basis of structural, computational, and reactivity studies as Schrock-type silylene complexes. Because of the presence of loosely bound Lewis base ligands, such silylene complexes readily undergo reaction with simple unsaturated hydrocarbons, such as alkynes, forming the corresponding [2 + 2] cycloaddition products.

3.
ACS Omega ; 4(2): 2902-2906, 2019 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-31459520

RESUMO

Novel unsaturated four-membered ring disilene, 3,3-dichloro-1,2,4,4-tetrakis[di-tert-butyl(methyl)silyl]-1Δ-1,2,3,4-trisilagermetene, was synthesized by the ring expansion reaction of the three-membered ring 1-disilagermirene with the silylene-NHC complex Cl2Si-IPr. The mechanism of the unexpected formation of this compound was verified by high-level density functional theory computations, which revealed nSi:(HOMO)-πSi=Si(LUMO) * as the dominant orbital interaction.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa